Linezolid Hikma

Linezolid, the active ingredient in Linezolid Hikma, is an oxazolidinone presented as an injectable solution for intravenous use. It treats infections caused by resistant Gram‑positive bacteria such as MRSA and VRE in hospitalized patients.

GNH USA supplies Linezolid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is indicated for serious Gram‑positive bacterial infections and is used in hospital settings for the following conditions: - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective against resistant strains, helping to clear the infection. - Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative treatment option for difficult‑to‑treat enterococcal disease. - Community‑acquired bacterial pneumonia: targets the causative Gram‑positive organisms and improves clinical outcomes. - Skin and soft tissue infections: reduces bacterial load in complicated cellulitis and wound infections. - Complicated intra‑abdominal infections: assists in controlling polymicrobial infections that include resistant Gram‑positive pathogens.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Myelosuppression (e.g., thrombocytopenia, anemia, leukopenia): requires regular blood count monitoring. - Peripheral neuropathy: sensory changes that may be irreversible if untreated. - Serotonin syndrome when combined with serotonergic agents: can present with agitation, hyperreflexia, and fever. - Lactic acidosis: rare metabolic disturbance needing immediate medical attention.

When prescribing linezolid, clinicians should consider several safety measures: - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes regularly during treatment. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Myelosuppression: perform complete blood count monitoring throughout therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): may cause severe hypertension. - Rifampicin: induces metabolism and reduces linezolid exposure.

Moderate Interactions (Monitor Closely): - Warfarin: linezolid may increase INR, requiring closer coagulation monitoring. - Theophylline: plasma concentrations can rise, necessitating dose adjustment. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk when combined.